Sponsor: MUSC
Sponsor Study ID: 103408
Study Title: A Phase 1B Trial of Tarloxotinib and Sotorasib in Patients with KRAS G12C Mutations
CTO #: 103408
NCT Number: NCT05313009
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: Primary Objectives: To evaluate the RP2D, safety, and tolerability of tarloxotinib in combination with sotorasib in patients with KRAS G12C mutated advanced non-small cell lung cancer (NSCLC). To evaluate the tumor objective response rate (ORR) assessed by RECIST 1.1 criteria of the combination of tarloxotinib with sotorasib. Secondary Objectives To evaluate other measures of efficacy of the combination of tarloxotinib with sotorasib in patient with KRAS G12C mutated advanced NSCLC